Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
AeQgGErHavsUdzGV
Listen
